0 10 Activation Activation NNP 11 13 of of IN 14 17 the the DT 18 23 human human JJ 24 40 immunodeficiency immunodeficiency NN 41 46 virus virus NN 47 51 type type NN 52 53 1 1 CD 54 62 enhancer enhancer NN 63 65 is be VBZ 66 69 not not RB 70 79 dependent dependent JJ 80 82 on on IN 83 89 NFAT-1 nfat-1 NN 89 90 . . . 92 95 The the DT 96 104 function function NN 105 107 of of IN 108 109 a a DT 110 118 putative putative JJ 119 125 NFAT-1 nfat-1 NN 126 130 site site NN 131 133 in in IN 134 137 the the DT 138 143 human human JJ 144 160 immunodeficiency immunodeficiency NN 161 166 virus virus NN 167 171 type type NN 172 173 1 1 CD 174 182 enhancer enhancer NN 183 186 has have VBZ 187 191 been be VBN 192 200 analyzed analyze VBN 200 201 . . . 202 212 Activation Activation NNP 213 215 by by IN 216 219 the the DT 220 226 T-cell t-cell NN 227 234 antigen antigen NN 235 243 receptor receptor NN 244 246 is be VBZ 247 254 minimal minimal JJ 255 257 in in IN 258 264 Jurkat Jurkat NNP 265 270 cells cell NNS 271 274 and and CC 275 277 is be VBZ 278 286 mediated mediate VBN 287 289 by by IN 290 293 the the DT 294 299 kappa kappa NN 300 301 B b NN 302 307 sites site NNS 307 308 . . . 309 312 The the DT 313 321 putative putative JJ 322 328 NFAT-1 nfat-1 NN 329 335 region region NN 336 338 is be VBZ 339 342 not not RB 343 351 required require VBN 352 355 for for IN 356 359 the the DT 360 368 response response NN 369 371 to to TO 372 380 anti-CD3 anti-cd3 NN 381 383 or or CC 384 386 to to TO 387 395 mitogens mitogen NNS 396 398 in in IN 399 405 T-cell T-cell NNP 405 406 , , , 407 413 B-cell B-cell NNP 413 414 , , , 415 417 or or CC 418 437 monocyte/macrophage monocyte/macrophage NN 438 446 leukemia leukemia NN 447 452 lines line NNS 452 453 , , , 454 457 nor nor CC 458 460 is be VBZ 461 463 it it PRP 464 465 a a DT 466 476 cis-acting cis-acting JJ 477 485 negative negative JJ 486 496 regulatory regulatory JJ 497 504 element element NN 504 505 . . .